IMUX Stock Discussion
Immunic, Inc. Description
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Autoimmune Disease Clinical Development Multiple Sclerosis Psoriasis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Mayo Clinic Primary Sclerosing Cholangitis Inflammatory And Autoimmune Diseases
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Popular Now
Featured Articles